Needham analyst Ami Fadia raised the firm’s price target on Axsome Therapeutics (AXSM) to $225 from $169 and keeps a Buy rating on the shares. The firm sees traction in 2026 for the company, based on potential approval and launch of Auvelity in Alzheimer’s disease agitation and pipeline development. Needham also expects continued strong performance of Auvelity in major depressive disorder.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $200 from $185 at H.C. Wainwright
- Top 5 Trending Stocks by Unusual Trading Volume, 1/1/26
- Axsome Therapeutics price target raised to $217 from $202 at Mizuho
- Axsome Therapeutics rises 19.4%
- Axsome Therapeutics: Late-Stage CNS Pipeline and Regulatory Tailwinds Support Buy Rating